Please provide your email address to receive an email when new articles are posted on . Anti-VEGF injections can help maintain and sometimes improve visual acuity in patients with degenerative retinal ...

Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.

When even the most highly trained surgeons perform procedures on the retina-one of the smallest, most delicate parts of the human body-the stakes are high. Surgeons must account for patients' ...

EYLEA Now Approved for Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Macular Edema following RVO TARRYTOWN, N.Y., Oct. 6, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals ...

Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

TARRYTOWN, N.Y., June 26, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for ...

The demand for intravitreal vascular endothelial growth factor (VEGF) inhibitor therapy is forecasted to increase by about 50% over the next 5 years in Denmark, due largely to an aging population, a ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Retinal specialists need to weigh the risk for vision loss against the risk for COVID-19 when ...